De Brauw advised underwriters on secondary offering of shares in NewAmsterdam Pharma. NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company developing oral, non-statin medicines for patients...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented the initial purchasers in the offering. Cerence Inc. (NASDAQ: CRNC) announced the pricing of $190.0 million aggregate principal amount of 1.50% convertible...
You must be a Standard 1 Year member to access this content.
Davis Polk advised BofA Securities, Inc., SVB Securities LLC on the offering. Cooley LLP represented Oculis Holding in the offering. Vischer AG advised Oculis Holding for...
You must be a Standard 1 Year member to access this content.
Cooley advises Vaxcyte on the offering, and Latham & Watkins advises the underwriters. Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering...
You must be a Standard 1 Year member to access this content.
Latham & Watkins is advising Revolution Medicines on the offering, and Davis Polk is advising the underwriters involved. Revolution Medicines, Inc. (Nasdaq: RVMD) has announced the...
You must be a Standard 1 Year member to access this content.
Cooley advises Travere Therapeutics, and Latham & Watkins advises the underwriters. Travere Therapeutics, Inc. (Nasdaq: TVTX) has announced the pricing of an underwritten public offering of...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer advised sales agents Goldman Sachs & Co. LLC and SVB Securities on the deal. Goldman Sachs & Co. LLC and SVB Securities acted as sales agents in...
You must be a Standard 1 Year member to access this content.
Gide advised financial advisers SVB Securities, LifeSci Capital and Bryan and Garnier & Co. The banks were also advised by Cooley LLP on aspects of US...
You must be a Standard 1 Year member to access this content.
NautaDutilh and Davis Polk advised CureVac on the offering, while Latham & Watkins advised the underwriters involved. CureVac N.V. announced the pricing of 27,027,028 common shares...
You must be a Standard 1 Year member to access this content.
Cooley LLP represented Structure Therapeutics, while Latham & Watkins LLP represented the underwriters in the offering. Structure Therapeutics, a clinical-stage global biopharmaceutical company, announced its $185.3 million...
You must be a Standard 1 Year member to access this content.
Davis Polk & Wardwell represented Roivant Sciences, while Latham & Watkins represented the underwriters in the offering. Roivant Sciences (Nasdaq: ROIV) has announced its $230 million...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini and Latham & Watkins advised Prometheus Biosciences on the deal, while Davis Polk & Wardwell advised the representatives of the several underwriters. Prometheus Biosciences,...
You must be a Standard 1 Year member to access this content.
